Precision BioSciences Receives Favorable Type C Feedback From FDA On Company's Chemistry, Manufacturing And Controls Strategies For Late-Stage Development Of Azercabtagene Zapreleucel, Its Lead Allogeneic CAR T Clinical Candidate

Benzinga · 01/06/2023 12:02

FDA feedback signals the Company's CMC plans shared are in alignment with Agency requirements and expectations